Gelteq Limited UNDERWRITING AGREEMENTUnderwriting Agreement • October 30th, 2024 • Gelteq LTD • Pharmaceutical preparations • New York
Executive Service Agreement Gelteq Pty Ltd and Simon Hayden SzewachExecutive Service Agreement • July 15th, 2024 • Gelteq LTD • Pharmaceutical preparations • Victoria
Gelteq Limited UNDERWRITING AGREEMENTUnderwriting Agreement • February 29th, 2024 • Gelteq LTD • Pharmaceutical preparations • New York
ContractShare Sale Agreement • July 15th, 2024 • Gelteq LTD • Pharmaceutical preparations
Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
ContractShare Sale Agreement • July 15th, 2024 • Gelteq LTD • Pharmaceutical preparations
Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
CONSULTING AGREEMENTConsulting Agreement • July 15th, 2024 • Gelteq LTD • Pharmaceutical preparations • New York
WHEREAS the Company has requested the Contractor to perform certain Services as hereinafter set forth and the Contractor has agreed to perform such Services on and subject to the terms and conditions hereinafter contained;
ContractLoan Agreement • July 15th, 2024 • Gelteq LTD • Pharmaceutical preparations
Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
MASTER RESEARCH SERVICES AGREEMENTMaster Research Services Agreement • July 15th, 2024 • Gelteq LTD • Pharmaceutical preparations
Gelteq Limited UNDERWRITING AGREEMENTUnderwriting Agreement • March 17th, 2023 • Gelteq LTD • Pharmaceutical preparations • Delaware
ContractGelteq Authorised Licensee Agreement • July 15th, 2024 • Gelteq LTD • Pharmaceutical preparations
Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.
CONSULTING AGREEMENTConsulting Agreement • August 30th, 2022 • Gelteq LTD • Pharmaceutical preparations • New York
THIS CONSULTING AGREEMENT (“Agreement”) is entered into on the 24 March 2022 by and between Ocean Street Partners, Inc. (hereinafter “Consultant”) and GelTeq Pty Ltd, an Australian corporation (hereinafter “Company”).
Parties Adjutor Healthcare Pty Ltd Gelteq Pty Ltd Master Services AgreementMaster Services Agreement • July 15th, 2024 • Gelteq LTD • Pharmaceutical preparations
Variation AgreementVariation Agreement • August 30th, 2022 • Gelteq LTD • Pharmaceutical preparations
CONSULTING AGREEMENTConsulting Agreement • February 29th, 2024 • Gelteq LTD • Pharmaceutical preparations • New York
THIS CONSULTING AGREEMENT (“Agreement”) is entered into on the 15th day of October 2023 by and between Ocean Street Partners, Inc. (hereinafter “Consultant”) and Gelteq Ltd, an Australian corporation (hereinafter “Company”).
AGREEMENT FOR THE PROVISION OF OFFICE SPACEAgreement for the Provision of Office Space • July 15th, 2024 • Gelteq LTD • Pharmaceutical preparations • Victoria
Gelteq Authorised Licensee Agreement – Pilot ProgramGelteq Authorised Licensee Agreement • August 30th, 2022 • Gelteq LTD • Pharmaceutical preparations
Key Terms – Private Label AgreementPrivate Label Agreement • July 15th, 2024 • Gelteq LTD • Pharmaceutical preparations • Victoria
Representative’s WarrantRepresentative’s Warrant • October 30th, 2024 • Gelteq LTD • Pharmaceutical preparations • Delaware
THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES BY HIS, HER OR ITS ACCEPTANCE HEREOF, THAT SUCH HOLDER WILL NOT FOR A PERIOD OF SIX (6) MONTHS FOLLOWING THE COMMENCEMENT OF SALES OF ORDINARY SHARES IN THE OFFERING (AS DEFINED BELOW): (A) SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT TO ANYONE OTHER THAN OFFICERS OR PARTNERS OF THE BENCHMARK COMPANY, LLC, EACH OF WHOM SHALL HAVE AGREED TO THE RESTRICTIONS CONTAINED HEREIN, IN ACCORDANCE WITH FINRA CONDUCT RULE 5110(E)(1), OR (B) CAUSE THIS PURCHASE WARRANT OR THE SECURITIES ISSUABLE HEREUNDER TO BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF THIS PURCHASE WARRANT OR THE SECURITIES HEREUNDER, EXCEPT AS PROVIDED FOR IN FINRA RULE 5110(E)(2).
WASATCH FORMULATION DEVELOPMENT AGREEMENTFormulation Development Agreement • August 30th, 2022 • Gelteq LTD • Pharmaceutical preparations • Utah
This Formulation Development Agreement (“Agreement”) is entered into by and between Wasatch Product Development LLC, a Developer organized under the laws of Utah, having its principal place of business at 427 West 11950 South, Draper, Utah 84020 (“Developer”) and Gelteq Pty Ltd a Developer organized under the laws of Victoria, Australia, having its principal place of business at 641 Glenhuntly Rd, Caulfield Victoria 3162 (“Client”) as of the 1st day of February , 2022 (“Effective Date”).
ContractLicense Agreement • July 15th, 2024 • Gelteq LTD • Pharmaceutical preparations
Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.
ContractLoan Agreement • July 15th, 2024 • Gelteq LTD • Pharmaceutical preparations
Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential
ContractLoan Agreement • December 5th, 2023 • Gelteq LTD • Pharmaceutical preparations
Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential
ContractLoan Variation Agreement • February 29th, 2024 • Gelteq LTD • Pharmaceutical preparations
Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential
